Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions. Its sole approved medicine is TEMBEXA (brincidofovir), a lipid conjugate designed to combat smallpox by inhibiting viral DNA synthesis, positioned as a critical medical countermeasure. Beyond its commercial offering, Chimerix boasts a robust clinical-stage pipeline: ONC201 targets recurrent diffuse midline glioma in patients whose tumors possess the H3 K27M mutation.